These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Implications of 4S evidence on baseline lipid levels. Jacobson TA Lancet; 1995 Jul; 346(8968):181-2. PubMed ID: 7603245 [No Abstract] [Full Text] [Related]
25. Fire-and-forget in prevention of coronary heart disease. Karpe F; Holman R Lancet; 2002 Dec; 360(9349):1984; author reply 1984. PubMed ID: 12493308 [No Abstract] [Full Text] [Related]
26. Lipid-lowering drugs and homocysteine. de Lorgeril M; Salen P; Paillard F; Lacan P; Richard G Lancet; 1999 Jan; 353(9148):209-10. PubMed ID: 9923885 [No Abstract] [Full Text] [Related]
27. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. Gaspoz JM; Coxson PG; Goldman PA; Williams LW; Kuntz KM; Hunink MG; Goldman L N Engl J Med; 2002 Jun; 346(23):1800-6. PubMed ID: 12050341 [TBL] [Abstract][Full Text] [Related]
28. After the meta-analyses: a commentary on treatment of dyslipidaemia in the primary prevention of coronary heart disease. Silberberg JS Aust N Z J Med; 1994 Dec; 24(6):717-21. PubMed ID: 7717926 [No Abstract] [Full Text] [Related]
30. National service framework for coronary heart disease. Ambiguities need to be clarified. Lloyd-Mostyn R BMJ; 2000 Sep; 321(7261):634. PubMed ID: 11023318 [No Abstract] [Full Text] [Related]
31. Gas chromatography analysis of serum cholesterol synthesis and absorption markers used to predict the efficacy of simvastatin in patients with coronary heart disease. Wu WF; Wang QH; Zhang T; Mi SH; Liu Y; Wang LY Clin Biochem; 2013 Aug; 46(12):993-998. PubMed ID: 23598259 [TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada. Rivière M; Wang S; Leclerc C; Fitzsimon C; Tretiak R CMAJ; 1997 Apr; 156(7):991-7. PubMed ID: 9099167 [TBL] [Abstract][Full Text] [Related]